RESEARCH TRIANGLE PARK, N.C., July 27, 2016 /PRNewswire/ -- Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, announced today that it will present at the Ophthalmic Drug Development Summit taking place July 26 – 28, 2016 in Washington, DC.
Dr. Tomas Navratil, Senior Vice President, Development at Envisia will present Targeting Leading Causes of Blindness with Nano and Micro Technology-Based Sustained Drug Delivery from 1:30 - 2:00pm Eastern Time on Thursday, July 28, 2016.
Envisia is leveraging the Company's unique PRINT® platform technology to develop products for the three leading causes of vision loss and blindness – glaucoma, age-related macular degeneration (AMD), and diabetic macular edema (DME).
ABOUT ENVISIA THERAPEUTICS™ Envisia Therapeutics is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology platform to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, extended-release formulation of a marketed prostaglandin analogue with the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is actively exploring the use of the company's unique technology to develop products for other important ocular diseases including age-related macular degeneration (AMD) and diabetic macular edema (DME). Envisia is located in Research Triangle Park, North Carolina. For more information, please go to www.envisiatherapeutics.com.